Initial real-world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study - PubMed
5 hours ago
- #Alzheimer's disease
- #Japan
- #real-world evidence
- Lecanemab, an anti-amyloid-beta antibody, is approved in over 40 countries.
- The study examined early real-world lecanemab use in Japan using claims data from 18 municipalities.
- 123 lecanemab recipients were identified, with a median age of 76 years and 73.2% being women.
- Most patients had mild cognitive impairment: 60.9% with MMSE ≥24 and 79.3% with CDR 0.5.
- The discontinuation rate was 1.04/100 person-months, with most discontinuations occurring within 1.5 months.
- Lecanemab was mainly prescribed to older women with milder cognitive impairment in Japan.
- Early discontinuation may reflect cautious adoption of lecanemab in Japan.
- The study was partially funded by Eisai Co., Ltd. and Biogen, but sponsors had no role in study design or execution.